Implanted Cell Device Reaches 5 Year Milestone
Source: Stefan Quenneville  (9/16/24)
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. More >

Trial Data Help Position Cell Pouch for Commercial Success
Source: Dr. Joseph Pantginis  (9/16/24)
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. More >

Is It Now Time To Buy This Biotech Stock?
Source: Clive Maund  (9/16/24)
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows. More >

California Biotech Reports Positive QOL Improvements in Program
Source: Dr. Jonathan Aschoff  (9/13/24)
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating. More >

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment
Source: Streetwise Reports  (9/12/24)
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure. More >

Biotech Working on 'Functional Cure' for Type 1 Diabetes
Source: Streetwise Reports  (9/10/24)
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients. More >

MA Biotech Reports Positive Meeting with FDA
Source: Dr. Benjamin Paluch  (9/9/24)
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note. More >

Mass. Biopharma Reports Positive Data and Announces New Program
Source: Dr. David Nierengarten  (9/6/24)
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts. More >

Pharma Co. Enrolls First Patient in Trial
Source: Dr. Joseph Pantginis  (9/5/24)
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy. More >

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial
Source: Streetwise Reports  (8/16/24)
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock. More >

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.
Source: Streetwise Reports  (8/9/24)
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy. More >

Boston Biotech Reports Promising Interim Data
Source: Dr. Swayampakula Ramakanth  (8/7/24)
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. More >

Analyst Says CA Pharma Underappreciated by Investors
Source: Patrick Trucchio  (7/23/24)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. More >

Analyst's Target Price for Biotech Massively Higher Than Current Price
Source: Dr. Leland Gershell  (7/22/24)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. More >

Study Shows 93% Cough Suppression With Co.'s Drug
Source: Streetwise Reports  (7/18/24)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." More >

Could This Stock Be the Next Bellus Cough Treatment?
Source: Clive Maund  (7/17/24)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. More >

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Source: Dr. Raghuram Selvaraju  (7/15/24)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Reports Strong FQ224 Results Driven
Source: Dr. Douglas Loe  (7/11/24)
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX). More >

Texas Biotech Announces Plans for Preclinical Obesity Studies
Source: Dr. Jonathan Aschoff  (7/8/24)
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. More >

AI Health Stock Heading Higher Expert Says
Source: Clive Maund  (7/2/24)
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. More >

California Biotech Reports Positive Phase 3 Results
Source: Ed Arce  (6/25/24)
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. More >

Clean Tech Subsidiary Finds Manufacturer for Wound Solution
Source: Streetwise Reports  (6/14/24)
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic. More >

Is This Pharma Co. the Next Eli Lilly?
Source: Streetwise Reports  (6/11/24)
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly. More >

Rare Disease Co. Presents Positive Phase 2 KP1077 Data
Source: Dr. Jonathan Aschoff  (6/6/24)
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note. More >

Pharma Co. Secures $650M Strategic Financing
Source: Edward Nash  (5/16/24)
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine. More >